Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391025 · ClinicalTrials.gov registry record · Early Phase 1
Gallium-68 Citrate PET Used in Prostate Cancer
A Early Phase 1 study of Prostatic Neoplasms, sponsored by Rahul Aggarwal.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02391025 is a Early Phase 1 study of Prostatic Neoplasms that has completed, run by Rahul Aggarwal. The registered enrollment target is 39 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02391025, a Early Phase 1 study of Prostatic Neoplasms, has completed, sponsored by Rahul Aggarwal.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will consist of participants with metastatic castration-resistant prostate cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001 (CC#125519), with evidence of resistance to androgen signaling inhibition.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Gallium-68 citrate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-05-28 |
| Est. Completion | 2023-06-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02391025
The ClinicalTrials.gov registry entry for NCT02391025 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (92% lower). The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT02391025 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02391025 about?
NCT02391025 is a clinical study titled "Gallium-68 Citrate PET Used in Prostate Cancer". This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will con...
What is the current status of trial NCT02391025?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2015-05-28. Estimated completion is 2023-06-15.
What conditions does trial NCT02391025 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02391025?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), Gallium-68 citrate (DRUG).
Who is sponsoring clinical trial NCT02391025?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02391025 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-DCFBC PET/CT in Prostate Cancer
COMPLETED · Early Phase 1
-
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
COMPLETED · Early Phase 1
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.